Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)

Learn more about:
Related Clinical Trial
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC Feasibility of [11C]Acetate-Positron Emission Tomography (PET) in Lymphangioleiomyomatosis and Tuberous Sclerosis Complex Lymphangioleiomyomatosis, a Study on Cathepsin K Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy KidneYou – Innovative Digital Therapy Gait in Rare Diseases Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants Doxycycline In Lymphangioleiomyomatosis (LAM) Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women Turmeric as Treatment in Epilepsy Study of the Disease Process of Lymphangioleiomyomatosis RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM The Effectiveness and Safety of Vagus Nerve Stimulation for TRE The Effectiveness and Safety of Resective Epilepsy Surgery for TRE Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) Safety of Simvastatin in LAM and TSC Studies of Autistic Patients: Gene Networks and Clinical Subtypes Topical Rapamycin to Erase Angiofibromas in TSC Rapalogues for Autism Phenotype in TSC: A Feasibility Study A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD Everolimus for Cancer With TSC1 or TSC2 Mutation Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex The Cognitive Variability in NF1 and TSC Monozygotic Twins Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy – Tuberous Sclerosis Complex A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC) Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex JASPER Early Intervention for Tuberous Sclerosis Studies in Patients With Tuberous Sclerosis Complex Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex (TuScCom) Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC) Tuberous Sclerosis Complex Natural History Study: Renal Manifestations Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) Study of Skin Tumors in Tuberous Sclerosis

Brief Title

Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)

Official Title

A Phase 2 Open-label 12-Week Trial of Adjunctive Ganaxolone Treatment (Part A) in Tuberous Sclerosis Complex-related Epilepsy Followed by Long-term Treatment (Part B)

Brief Summary

      To assess preliminary safety and efficacy of ganaxolone as adjunctive therapy for the
      treatment of primary seizure types in patients with genetically- or clinically-confirmed
      TSC-related epilepsy through the end of the 12 week treatment period.

Detailed Description

      This is an OL proof of concept study of adjunctive GNX treatment in patients with a confirmed
      clinical diagnosis of TSC and/or a mutation in either the TSC1 or TSC2 gene. The trial
      consists of two parts: Part A consists of a 4-week baseline period followed by a 12-week
      treatment period (4-week titration and 8-week maintenance). For patients not continuing in
      the 24-week OLE period (Part B), a 2-week taper period followed by a 2-week safety period
      would follow. The main difference between Part A and Part B is the length of treatment, less
      frequent assessments, and the ability to alter drug doses (both GNX and other antiepileptic
      drug [AED] treatments which includes initiating and stopping other medications) based on
      investigator evaluation of the patient's clinical course during Part B. Patients with a
      seizure frequency reduction during the 12-week treatment period in Part A compared to
      baseline may continue into Part B ("OLE eligible"), to assess long-term safety, efficacy and
      tolerability in patients with TSC-related Epilepsy.

Study Phase

Phase 2

Study Type


Primary Outcome

Percent Change in 28-day Seizure Frequency

Secondary Outcome

 Percentage of patients


Tuberous Sclerosis



Study Arms / Comparison Groups

Description:  ganaxolone suspension (50 mg/ml) TID for 12 weeks with 24 week extension


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

April 8, 2020

Completion Date

December 31, 2021

Primary Completion Date

June 30, 2021

Eligibility Criteria

        Inclusion Criteria (Part A):

          -  Clinical or mutational diagnosis of TSC

          -  Failure to control seizures despite appropriate trial of 2 or more ASMs at therapeutic

          -  Have at least 8 countable/witnessed primary seizures during the 4-week baseline period
             with at least 1 primary seizure occurring in at least 3 of the 4 weeks of baseline.

        Inclusion Criteria (Part B)

        • Patients have experienced ≥ 35% reduction in primary seizure frequency during the Part A
        treatment period compared to the 4-week Baseline Period.

        Exclusion Criteria (Part A):

          -  Previous exposure to GNX

          -  Pregnant or breastfeeding

          -  Concurrent use of strong inducers or inhibitors of cytochrome P450 (CYP)3A4/5/7. Any
             strong inhibitor or inducer of CYP3A4/5/7 must be discontinued at least 28 days before
             Visit 2, study drug initiation. This does not include approved ASMs.

          -  Patients who have been taking felbamate for less than 1 year prior to screening

          -  Patients who test positive for tetrahydrocannabinol (THC) or non-approved cannabidiol
             (CBD) via plasma drug screen

          -  Chronic use of oral steroid medications, ketoconazole (except for topical
             formulations), St. John's Wort, or other IPs is not permitted

          -  Have an active CNS infection, demyelinating disease, degenerative neurological
             disease, or CNS disease deemed progressive. This includes tumor growth which in the
             opinion of the investigator could affect primary seizure control

          -  Patients with significant renal insufficiency, estimated glomerular filtration rate
             (eGFR) < 30 mL/min (calculated using the Cockcroft-Gault formula or Pediatric GFR
             calculator or Bedside Schwartz), will be excluded from study entry or will be
             discontinued if the criterion is met post baseline

          -  Have been exposed to any other investigational drug within 30 days or fewer than 5
             half lives (whichever is shorter) prior to the screening visit




2 Years - 65 Years

Accepts Healthy Volunteers



Maciej Gasior, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Marinus Pharmaceuticals

Study Sponsor

Maciej Gasior, MD, Study Director, Marinus Pharmaceuticals, Inc.

Verification Date

May 2021